Literature DB >> 7906709

Progression of symptoms in neuroleptic malignant syndrome.

V R Velamoor1, R M Norman, S N Caroff, S C Mann, K A Sullivan, R E Antelo.   

Abstract

The neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disorder characterized by mental-status changes, muscle rigidity, hyperthermia, and autonomic dysfunction. Systematic examination of early signs and the progression of symptoms in NMS may be worthwhile to facilitate prompt recognition and interventions to abort the syndrome in its incipient stage. The authors present the results of a preliminary review of the temporal sequence of the four predominant signs of NMS as described in 340 clinical reports of NMS in the literature. Of all order implications, 70.5% were consistent with the sequence of mental-status changes, rigidity, hyperthermia, and autonomic dysfunction. Changes in either mental status or rigidity were the initial manifestations of NMS in 82.3% of cases with a single presenting sign and were significantly more likely to be observed before hyperthermia and autonomic dysfunction. Methodological limitations of these data and clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906709     DOI: 10.1097/00005053-199403000-00007

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  24 in total

Review 1.  Diagnosis and management of acute movement disorders.

Authors:  D Dressler; R Benecke
Journal:  J Neurol       Date:  2005-10-10       Impact factor: 4.849

2.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

3.  Muscle changes in the neuroleptic malignant syndrome.

Authors:  W M Behan; M Madigan; B J Clark; J Goldberg; D R McLellan
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

4.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

Review 5.  Controversies in Serotonin Syndrome Diagnosis and Management: A Review.

Authors:  Mohd Faisal Uddin; Richard Alweis; Syed Raza Shah; Noman Lateef; Waqas Shahnawaz; Rohan Kumar Ochani; Amin Muhammad Dharani; Syed Arbab Shah
Journal:  J Clin Diagn Res       Date:  2017-09-01

6.  An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.

Authors:  Roland van Rensburg; Eric H Decloedt
Journal:  Psychopharmacol Bull       Date:  2019-02-15

7.  [Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies].

Authors:  J González-Valcárcel; M R Rosenfeld; J Dalmau
Journal:  Neurologia       Date:  2010-09       Impact factor: 3.109

8.  Resolution of symptoms in neuroleptic malignant syndrome.

Authors:  Yvonne D S Pereira; Ashish Srivastava; Bramhanand S Cuncoliencar; Nayana Naik
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

Review 9.  The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity.

Authors:  M V Balzan
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

Review 10.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.